Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053814 | 0.84 | PTGDR2 (0.70) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL3373433 | 0.81 | PTGDR2 (0.67) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3372030 | 0.75 | PTGDR2 (0.56) | PTGDR2AKR1B1PPARGCYP2C9PTGDR | |
| SCHEMBL3372375 | 0.74 | PTGDR2 (0.72) | PTGDR2AKR1B1PTGDR | |
| SCHEMBL2053285 | 0.72 | PTGDR2 (0.70) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL2050555 | 0.72 | PTGDR2 (0.66) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL3374154 | 0.72 | PTGDR2 (0.55) | PTGDR2AKR1B1PPARG | |
| SCHEMBL2053697 | 0.71 | PTGDR2 (0.54) | PTGDR2AKR1B1PPARG | |
| SCHEMBL2050867 | 0.70 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9PTGDR | |
| SCHEMBL2050711 | 0.70 | PTGDR2 (0.74) | PTGDR2AKR1B1CYP2C9PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656347-B1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7709521-B2 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1656347-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | Astrazeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019171-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | IDO1, IDO2, TPH1 | PTGDR2 303/4885AKR1B1 296/4885PPARG 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.